Want to see HK:2251 full AI Analyst Report?
2251 Stock Chart & Stats
HK$12.44
-HK$0.02(-0.17%)
At close: 4:00 PM EST
HK$12.44
-HK$0.02(-0.17%)
Day’s Range― - ―
52-Week RangeHK$9.15 - HK$16.00
Previous CloseN/A
Volume16.00K
Average Volume (3M)61.23K
Market Cap
HK$948.35M
Enterprise ValueHK$457.44M
Total Cash (Recent Filing)HK$650.73M
Total Debt (Recent Filing)HK$26.93M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding101,955,610
10 Day Avg. Volume99,440
30 Day Avg. Volume61,230
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)0.85
Price to Sales (P/S)6.06
P/FCF Ratio-49.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)HK$251.57M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very low debt-to-equity ratio (~0.02 in 2025) materially reduces refinancing and interest burdens, preserving financial optionality to fund R&D, clinical validation and commercialization. This conservative capital structure supports multi-quarter strategic execution and flexibility.
Revenue & Margin ExpansionRevenue recovered to +15.3% in 2025 while gross margin expanded to ~66%, reflecting improving unit economics for core AI imaging products. Sustained higher gross margins provide durable room to invest in sales and product development while working toward operating profitability.
Scalable SaaS-like ModelThe business monetizes AI via access/licensing, per-use fees, subscriptions and screening services—effectively a SaaS-like, recurring model. As deployments scale across hospitals and screening programs, this revenue mix supports high gross margins and operational leverage over time.
Bears Say
Persistent LossesDespite margin and revenue improvements, the company still reported a net margin near -14% in 2025. Continued losses constrain internal funding for expansion and R&D, limit ROE recovery, and may require external capital or prolonged margin improvement to reach sustainable profitability.
Cash Flow VolatilityOperating and free cash flow were negative in 2025 and free cash flow deteriorated sharply versus 2024, with a multi-year pattern of large outflows. Unpredictable cash conversion elevates execution risk for scaled deployments and could force financing, diluting long-term returns.
Negative ROEROE is negative across all years presented, indicating deployed capital has not yet produced positive shareholder returns. Even with low leverage, persistent negative ROE highlights structural profitability and efficiency issues that must be addressed to create long-term shareholder value.
Beijing Airdoc Technology Co. Ltd. Class H News
2251 FAQ
What was Beijing Airdoc Technology Co. Ltd. Class H’s price range in the past 12 months?
Beijing Airdoc Technology Co. Ltd. Class H lowest stock price was HK$9.15 and its highest was HK$16.00 in the past 12 months.
What is Beijing Airdoc Technology Co. Ltd. Class H’s market cap?
Beijing Airdoc Technology Co. Ltd. Class H’s market cap is HK$948.35M.
When is Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date?
Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 18 days.
How were Beijing Airdoc Technology Co. Ltd. Class H’s earnings last quarter?
Beijing Airdoc Technology Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.249.
Is Beijing Airdoc Technology Co. Ltd. Class H overvalued?
According to Wall Street analysts Beijing Airdoc Technology Co. Ltd. Class H’s price is currently Overvalued.
Does Beijing Airdoc Technology Co. Ltd. Class H pay dividends?
Beijing Airdoc Technology Co. Ltd. Class H does not currently pay dividends.
What is Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate?
Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Airdoc Technology Co. Ltd. Class H have?
Beijing Airdoc Technology Co. Ltd. Class H has 101,955,610 shares outstanding.
What happened to Beijing Airdoc Technology Co. Ltd. Class H’s price movement after its last earnings report?
Beijing Airdoc Technology Co. Ltd. Class H reported an EPS of -HK$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.051%.
Which hedge fund is a major shareholder of Beijing Airdoc Technology Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2251
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Airdoc Technology Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.84%
Trailing 12-Months
Company Description
Beijing Airdoc Technology Co. Ltd. Class H
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
Technical Analysis
Ping An Healthcare and Technology Company
―
Yidu Tech, Inc.
―
Chaoju Eye Care Holdings Ltd.
―
C-MER Eye Care Holdings Limited
―
Zhaoke Ophthalmology Ltd.
―